一个可预防的阿尔茨海默氏症微针贴片,具有突触保护和NLRP3炎症抑制在戒烟期间微质中的炎症酶抑制
Huangjuan Li1, Meihua Li1, Chenglin Li1
1State Key Laboratory of Natural Medicines, Department of Pharmaceutical Science, School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198, China.
ACS nano
|February 16, 2026
概括
尼古丁替代疗法可以通过增加tau病理来恶化阿尔茨海默病 (AD). 一个新的微针贴片提供尼古丁用于戒烟和白醇以防止AD进展,保护突触和抑制神经炎症.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学 是一个学科.
- 生物医学工程 生物医学工程
背景情况:
- 长期吸烟是阿尔茨海默病 (AD) 的危险因素.
- 矛盾的是,尼古丁替代疗法 (NRT) 在戒烟期间可能会使病理恶化.
- 现有的NRT缺乏用于AD预防的神经保护策略.
研究的目的:
- 在戒烟期间开发微针贴片 (PADM) 以预防阿尔茨海默病.
- 研究尼古丁在突触完整性和神经炎症中的双重作用.
- 将尼古丁与白醇结合起来,以实现协同的神经保护.
主要方法:
- 设计了一个双层微针贴片,释放尼古丁 (NIC) 和复星 (RES).
- 在AD小鼠模型中研究了NIC对微质SIRPα,突触修剪,Aβ清除和NLRP3炎症酶激活的影响.
- 评估 RES 在抑制神经炎症和病理方面的疗效.
主要成果:
- 尼古丁通过上调微质SIRPα的调节,暂时增强了突触完整性和Aβ清除.
- 尼古丁还激活了NLRP3炎症体,导致陶过酸化.
- 带有持续NIC和RES输送的PADM补丁改善了认知,减少了Aβ负担,并预防了APP/PS1小鼠中的tau病理.
结论:
- 在戒烟期间,PADM微针贴片提供了一种双重作用的方法来预防AD.
- 这种策略可以减轻尼古丁的不良影响,同时利用其益处.
- PADM为高风险人群提供了一种新的预防性治疗方法.
更多相关视频
相关概念视频
Alzheimer's Disease: Treatment
994
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
994
Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K


